Alteplase is the only approved thrombolytic agent for acute ischaemic stroke. The overall benefit from alteplase is substantial, but some evidence indicates that alteplase also has negative effects on the ischaemic brain. Tenecteplase may be more effective and less harmfull than alteplase, but large randomised controlled phase 3 trials are lacking. The Norwegian Tenecteplase Stroke Trial (NOR-TEST) aims to compare efficacy and safety of tenecteplase vs. alteplase.
NOR-TEST is a multi-centre PROBE (prospective randomised, open-label, blinded endpoint) trial designed to establish superiority of tenecteplase 0.4?mg/kg (single bolus) as compared with alteplase 0.9?mg/kg (10% bolus?+?90% infusion/60?minutes) for consecutively admitted patients with acute ischaemic stroke eligible for thrombolytic therapy, i.e. patients a) admitted
Notes
Cites: Stroke. 2013 Feb;44(2):427-3123287781
Cites: N Engl J Med. 2013 Mar 7;368(10):893-90323390923
Cites: Lancet. 2000 May 13;355(9216):1670-410905241
Cites: Nat Med. 2001 Jan;7(1):59-6411135617
Cites: Stroke. 2001 Mar;32(3):748-5211239197
Cites: Stroke. 2004 Jan;35(1):109-1414671246
Cites: Lancet. 2004 Mar 6;363(9411):768-7415016487